RUCONEST SOLUTIONS™
Expertise. Delivered personally.

Patient Enrollment Form

Fax completed forms to: 1-855-423-5757

RUCONEST®
C1esterase inhibitor (recombinant)

Select which specialty pharmacy the patient currently uses (if known):
☐ Accredo Health Group ☐ AllianceRx Walgreens Prime ☐ CVS Caremark ☐ Humana SP ☐ Orsini

1. Prescription

Patient Name _____
DOB _____ Patient Weight _____kg/_____lbs
Diagnosis: ☐ ICD-10-CM D84.1 (Defects in the complement system [HAE])
☐ Other: _____

Prescription: RUCONEST 2100 international units (IU)/vial injection (50 IU/kg), Max 4200 IU

DIRECTIONS: Administer _____IU as a slow IV injection over 5 min PRN for attacks. No more than 2 doses within a 24-hour period

☐ 4 doses (8 vials) ☐ 8 doses (16 vials) ☐ **Per Month**
☐ 16 doses (32 vials) ☐ ____doses (____vials) ☐ **Per Shipment**

Refill 1 x year, unless noted otherwise
☐ 3 Refills ☐ 6 Refills ☐ 12 Refills ☐ _____ Refills

ANCILLARY ORDERS: Dispense infusion supplies with each prescription.
Dispense: One (1) vial of Sterile Water for Injection 14 mL per 2100 IU vial of RUCONEST

Flushing Orders
☐ Normal saline 3 mL or 5 mL intravenous (peripheral line) or 10 mL intravenous (central line) before and after infusion, or as needed for line patency
☐ Heparin 10 units/mL (#3mL or #5mL) use as a final flush for central line (QS)
☐ Heparin 100 units/mL (#3mL or #5mL) use as a final flush for central line (QS)

Anaphylaxis Order Specialty pharmacy to provide anaphylactic kit per provider protocol. Substitution permitted unless DAW specified _____

Epinephrine #2 pack ☐ 0.15mg ☐ 0.3mg **Refills:** _____
Inject IM as needed for anaphylaxis reaction. May repeat x 1 in 5 to 15 minutes if symptoms persist. SP to provide at first dispense.

Concurrent Medications _____

Drug/Non-Drug Allergies _____ ☐ No Known Allergies

☐ **Substitution permitted** ☐ **Dispense as written**

MD Sign

PRESCRIBER _____ Print _____ Date _____

I appoint Pharming Healthcare, Inc., RUCONEST SOLUTIONS, its affiliates, and their representatives on my behalf to convey this prescription described herein to the dispensing pharmacy by any means allowed under applicable law. I understand that I may not delegate signature authority.

2. Optional Prescription for StarterRx, Bridge-to-Therapy, and/or PAP Program

Patient Name _____
DOB _____ Patient Weight _____kg/ _____lbs
Diagnosis: ☐ ICD-10-CM D84.1 (Defects in the complement system [HAE])
☐ Other: _____

Prescription: RUCONEST 2100 IU/vial injection (50 IU/kg), Max 4200 IU

DIRECTIONS: Administer _____IU as a slow IV injection over 5 min PRN for attacks. No more than 2 doses within a 24-hour period

☐ 2 doses (4 vials) ☐ **Per Month**
☐ ____ doses (vials) ☐ **Per Shipment**

Refill 1 x year, unless noted otherwise ☐ _____Refills

ANCILLARY ORDERS: Dispense infusion supplies with each prescription.
Dispense: One (1) vial of Sterile Water for Injection 14 mL per 2100 IU vial of RUCONEST

Flushing Orders
☐ Normal saline 3 mL or 5 mL intravenous (peripheral line) or 10 mL intravenous (central line) before and after infusion, or as needed for line patency
☐ Heparin 10 units/mL (#3mL or #5mL) use as a final flush for central line (QS)
☐ Heparin 100 units/mL (#3mL or #5mL) use as a final flush for central line (QS)

Concurrent Medications _____

Drug/Non-Drug Allergies _____ ☐ No Known Allergies

☐ **Substitution permitted** ☐ **Dispense as written**

MD Sign

PRESCRIBER _____ Print _____ Date _____

I appoint Pharming Healthcare, Inc., RUCONEST SOLUTIONS, its affiliates, and their representatives on my behalf to convey this prescription described herein to the dispensing pharmacy by any means allowed under applicable law. I understand that I may not delegate signature authority.

3. Optional Nursing Orders for Specialty Pharmacy and/or Home Health Agency Infusions

Skilled nursing visit as needed to provide patient education related to therapy, disease state, self and/or nurse administer of medication as prescribed. Select training or infusion options (some patients may need both)

☐ Provide ongoing **self-administration** training until patient/caregiver is independent with self infusion
☐ Provide **ongoing nursing visits** for on demand infusions (PRN) ☐ M-F - 8/5 pm ☐ 24/7 ☐ Other _____

Visit frequency (based on medication order and dosage order) and patient's/caregiver's ability to self-administer _____

Inject epinephrine subcutaneously or intramuscularly for anaphylaxis reaction, may repeat in 5-15 minutes if no resolution. Call 911.

MD Sign

PRESCRIBER _____ Date _____

RUCONEST SOLUTIONS™
Expertise. Delivered personally.

Patient Enrollment Form

Fax completed forms to: 1-855-423-5757

RUCONEST®
C1esterase inhibitor (recombinant)

4. Patient Information

☐ **Attach copy of demographic/face sheet OR complete below**

Name _____ ☐ Male ☐ Female Last 4 digits of SSN _____ DOB _____

Check Preferred Phone # ☐ Work # _____ ☐ Home # _____ ☐ Cell # _____

Preferred Language _____

Email _____

Address _____

_____

City/State/ZIP _____

Caregiver Information

Caregiver Name (first, last) _____

Relationship to Patient _____

Caregiver Phone # _____ ☐ Okay to leave vm

Caregiver Email _____

5. Patient Insurance Information

☐ **Attach copies of front and back of all medical and prescription insurance cards OR complete below**

Medical Insurance Card

Plan Name _____

Plan Phone # _____

Policy Holder Name _____

Member ID # _____

Group # _____

Prescription Drug Card

PBM/Plan Name _____

Plan Phone # _____

Member ID # _____

BIN # _____

PCN # _____ Group # _____

MD Sign I attest that I have a HIPAA form on file and RUCONEST Solutions is authorized to perform a benefits verification. PRESCRIBER INITIALS: _____

6. Prescriber Information

Provider Specialty: ☐ **Allergy** ☐ **Dermatology** ☐ **GI** ☐ **Immunology** ☐ **Primary Care** ☐ **Other** _____

Provider Name _____ NPI # _____ TIN # _____

Medicaid Provider ID # _____ State License # _____ PTAN # _____

Site Name _____

Address _____

_____

City/State/ZIP _____

Phone _____ Fax # _____

Office Contact Information

Contact Name _____

Role _____

Contact Phone _____

Contact Email _____

7. Additional Communications by Pharming Healthcare to Patients

Please sign below if you agree to receive information about RUCONEST and live HAE educational programs. Pharming Healthcare, Inc. or any of the company affiliates may contact you via mail, email and/or phone. Your information will be kept confidential and will not be sold or leased to third parties.

Patient Sign **Signature** _____ **Date** _____

Please see accompanying full Prescribing Information.

RUCONEST SOLUTIONS™
Expertise. Delivered personally.

Patient Enrollment Form

Fax completed forms to: 1-855-423-5757

RUCONEST®
C1esterase inhibitor (recombinant)

1. I am participating in the RUCONEST SOLUTIONS Program ("Program") operated by Pharming Healthcare Inc. which provides me certain clinical and nursing support services related to my use of the biologic RUCONEST, manufactured by Pharming Healthcare Inc., for treatment of my HAE condition. The Program is administered by the Lash Group. This authorization will allow Pharming Healthcare Inc., the Lash Group, my pharmacy, healthcare providers, and health plan to use and disclose certain health information about me to facilitate my treatment with RUCONEST and to improve the Program for the benefit of future patients with HAE. I hereby authorize the use or disclosure of my protected health information (PHI) defined below for the purposes described in Section 5 below. I understand that this authorization is voluntary. I understand that if the organization authorized to receive and use my PHI is not a health plan or healthcare provider, the released information may no longer be protected by federal privacy regulations and there is a potential for my PHI to be subject to redisclosure by the recipients.

2. Persons/organizations who may disclose my PHI:
   - Pharming Healthcare Inc. and its authorized representatives ("Pharming")
   - Lash Group
   - My pharmacy(ies) providing the RUCONEST
   - My healthcare provider(s), including physicians and home care nurse educators
   - My health plan(s) providing medical care and prescription coverage

3. Persons/organizations who may receive and use my PHI:
   - Pharming Healthcare Inc. and its authorized representatives
   - Lash Group
   - My pharmacy(ies) that provide RUCONEST
   - My healthcare provider(s), including physicians and home care nurse educators
   - My health plan(s) providing medical care and prescription coverage

4. My PHI consists of the following information about me that may be used or disclosed:
   - Information I provided on the RUCONEST Enrollment Form
   - My healthcare records related to my treatment and HAE condition
   - My health insurance information regarding my coverage, copay, deductibles, and benefit options
   - My prescription information, such as status, fulfillment, and/or shipment of my medication
   - My hospital records for any hospitalization and information related to my transition of care

5. My PHI may be used and disclosed for the following purposes:
   - Coordinating my insurance coverage, Starter/Bridge/samples, product administration training, prescription shipments, and other treatment support
   - Tracking items such as health/prescription plan coverage, patient cost, shipments of the RUCONEST, health plan coverage trends, use of the Program offerings
   - Assessing ongoing and future needs of patients who are prescribed RUCONEST
   - Analyzing the quality, efficacy, and safety of RUCONEST

6. I understand that the specialty pharmacies that dispense my medication may be paid for sharing my PHI , and/or for providing patient support services pursuant to the authorization with the Program and Pharming so that the recipients may use it for the purposes specified in this authorization.

7. My authorization will remain in effect for two (2) years from the date of my signature unless I revoke it before then or a shorter time frame is mandated by state law. I understand that I may be requested to provide my written authorization on an annual basis by the Program to support continued access to my PHI. I understand that after I have signed this authorization, I may revoke it at any time by sending a written notice to the RUCONEST SOLUTIONS Program at PO Box 221974, Charlotte, NC 28222-1974. The revocation goes in effect once it has been received by the RUCONEST SOLUTIONS Program, and my healthcare providers and health plan, but the revocation will not affect any of my PHI already disclosed in reliance on this authorization.

8. I understand that I can refuse to sign this authorization and it will not affect the start, continuation, or quality of my treatment from my healthcare provider, payment for my treatment or my eligibility for or enrollment in health coverage.

   However, I understand that if I choose not to sign this authorization or revoke it after signing this form, the Program will not be able to provide me with the support described above, after the date of revocation.

9. I understand that I am entitled to a copy of this Authorization after signing below.

10. I authorize RUCONEST SOLUTIONS, my doctor, my pharmacist, or any representative attempting to provide me with access to RUCONEST to contact the emergency contact listed below on my behalf in the event of an emergency.

Emergency Contact

Name _____

Relationship _____ Phone _____

Patient Sign

Patient's signature _____ Date _____

Printed Name _____

OR

Patient Rep Sign

Signature of patient's representative _____ Date _____

Printed name of representative _____ Relationship to patient _____